Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorodeoxyglucose F18 | 12 | 2023 | 138 | 1.570 |
Why?
|
| Positron-Emission Tomography | 13 | 2020 | 329 | 1.570 |
Why?
|
| Radiopharmaceuticals | 6 | 2020 | 179 | 0.780 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 240 | 0.520 |
Why?
|
| Lung Neoplasms | 7 | 2018 | 2261 | 0.450 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2022 | 25 | 0.420 |
Why?
|
| Cysts | 2 | 2010 | 104 | 0.420 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2010 | 138 | 0.420 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 151 | 0.390 |
Why?
|
| Duodenal Diseases | 1 | 2010 | 24 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2015 | 2598 | 0.370 |
Why?
|
| Multimodal Imaging | 3 | 2015 | 110 | 0.340 |
Why?
|
| Whole Body Imaging | 4 | 2015 | 41 | 0.300 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2016 | 1204 | 0.290 |
Why?
|
| Technetium | 2 | 2022 | 28 | 0.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2018 | 1074 | 0.280 |
Why?
|
| Tumor Burden | 6 | 2023 | 288 | 0.270 |
Why?
|
| Radionuclide Imaging | 4 | 2018 | 220 | 0.250 |
Why?
|
| Subtraction Technique | 3 | 2011 | 133 | 0.240 |
Why?
|
| Colitis, Ulcerative | 1 | 2009 | 711 | 0.210 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.210 |
Why?
|
| Erythrocytes | 1 | 2003 | 255 | 0.210 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 229 | 0.190 |
Why?
|
| Sarcoidosis | 1 | 2020 | 71 | 0.190 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 663 | 0.180 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 115 | 0.180 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 159 | 0.180 |
Why?
|
| Image Enhancement | 3 | 2014 | 563 | 0.170 |
Why?
|
| Bone and Bones | 3 | 2011 | 265 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 86 | 0.150 |
Why?
|
| Retrospective Studies | 8 | 2023 | 8464 | 0.150 |
Why?
|
| Female | 17 | 2020 | 44489 | 0.140 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 21 | 0.140 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2016 | 35 | 0.140 |
Why?
|
| Humans | 26 | 2023 | 86526 | 0.140 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2011 | 332 | 0.140 |
Why?
|
| Male | 17 | 2020 | 40944 | 0.140 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2011 | 466 | 0.140 |
Why?
|
| Aged | 10 | 2020 | 18398 | 0.130 |
Why?
|
| Middle Aged | 11 | 2020 | 25013 | 0.130 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2016 | 73 | 0.130 |
Why?
|
| Neuroblastoma | 1 | 2018 | 374 | 0.130 |
Why?
|
| Cystic Duct | 1 | 2014 | 5 | 0.130 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2014 | 11 | 0.130 |
Why?
|
| Cholecystitis, Acute | 1 | 2014 | 7 | 0.130 |
Why?
|
| Gallbladder | 1 | 2014 | 30 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1267 | 0.120 |
Why?
|
| Prognosis | 4 | 2023 | 3673 | 0.120 |
Why?
|
| Aspartic Acid | 1 | 2013 | 64 | 0.110 |
Why?
|
| Gadolinium DTPA | 1 | 2014 | 261 | 0.110 |
Why?
|
| Prealbumin | 2 | 2022 | 34 | 0.110 |
Why?
|
| Adult | 8 | 2015 | 25627 | 0.110 |
Why?
|
| Sirolimus | 1 | 2013 | 169 | 0.110 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 164 | 0.100 |
Why?
|
| Artificial Intelligence | 2 | 2011 | 295 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 170 | 0.100 |
Why?
|
| False Negative Reactions | 1 | 2010 | 63 | 0.100 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 62 | 0.090 |
Why?
|
| Radiosurgery | 1 | 2012 | 272 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 382 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 425 | 0.090 |
Why?
|
| Bone Neoplasms | 2 | 2010 | 322 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6501 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 620 | 0.080 |
Why?
|
| Echo-Planar Imaging | 1 | 2007 | 52 | 0.080 |
Why?
|
| Remission Induction | 1 | 2009 | 722 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 763 | 0.080 |
Why?
|
| Brain Diseases | 1 | 2007 | 180 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1564 | 0.070 |
Why?
|
| Young Adult | 3 | 2018 | 5971 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 1937 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 217 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1461 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2013 | 1056 | 0.060 |
Why?
|
| Inflammation | 1 | 2009 | 919 | 0.060 |
Why?
|
| Digestive System | 1 | 2003 | 42 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1671 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2705 | 0.060 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 9 | 0.060 |
Why?
|
| Diphosphates | 1 | 2022 | 18 | 0.060 |
Why?
|
| Angiography | 1 | 2003 | 208 | 0.050 |
Why?
|
| Biomarkers | 2 | 2022 | 1716 | 0.050 |
Why?
|
| Adolescent | 2 | 2018 | 8976 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2357 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 39 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 1239 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 49 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 1860 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2014 | 4208 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2007 | 2261 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 448 | 0.040 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2018 | 19 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 159 | 0.040 |
Why?
|
| Neoplasms | 1 | 2012 | 2895 | 0.040 |
Why?
|
| Observer Variation | 2 | 2010 | 602 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1307 | 0.040 |
Why?
|
| Trinucleotide Repeats | 1 | 2016 | 31 | 0.040 |
Why?
|
| Corpus Striatum | 1 | 2016 | 86 | 0.030 |
Why?
|
| Calcium Channels | 1 | 2016 | 182 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1195 | 0.030 |
Why?
|
| ROC Curve | 2 | 2007 | 752 | 0.030 |
Why?
|
| Everolimus | 1 | 2013 | 40 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 860 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 318 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 3040 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1803 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 3610 | 0.030 |
Why?
|
| Algorithms | 2 | 2011 | 1830 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 396 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 3960 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2013 | 7981 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 114 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 1077 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2011 | 234 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2765 | 0.020 |
Why?
|
| Pineal Gland | 1 | 2007 | 14 | 0.020 |
Why?
|
| Texas | 1 | 2007 | 101 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2007 | 54 | 0.020 |
Why?
|
| Child | 1 | 2018 | 6921 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 674 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2006 | 216 | 0.020 |
Why?
|
| Automation | 1 | 2006 | 106 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3636 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 5209 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1988 | 0.010 |
Why?
|
| Software | 1 | 2006 | 654 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3350 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 1168 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 2214 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5413 | 0.010 |
Why?
|